Physician profile
Yvette David
NPI 1134219710
$270,835.86
in general payments reported to CMS, 2019-2025
18 companies · $83K in 2025
The $83K reported for 2025 was more than what 98% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $34K · 2020: $21K · 2021: $25K · 2022: $25K · 2023: $24K · 2024: $60K · 2025: $83K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $132K · Travel and Lodging: $29K · Food and Beverage: $5,354 · Gift: $20.46.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $132,450.00 |
| Travel and Lodging | $28,778.50 |
| Food and Beverage | $5,354.11 |
| Gift | $20.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $267,245.63 | 2019-2025 | Skyrizi, Rinvoq, Qulipta |
| Gilead Sciences, INC. | $2,434.16 | 2020-2023 | Epclusa |
| Janssen Biotech, INC. | $332.08 | 2022-2025 | Tremfya, Stelara, Simponi |
| Braintree Laboratories, INC. | $230.18 | 2019-2023 | Suflave |
| Pfizer INC. | $125.69 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $116.73 | 2023-2025 | Dupixent |
| Phathom Pharmaceuticals, INC. | $52.53 | 2024-2025 | Voquezna |
| Boston Scientific Corporation | $44.56 | 2019 | |
| Genzyme Corporation | $41.70 | 2024 | |
| Madrigal Pharmaceuticals | $34.39 | 2024-2025 | Rezdiffra, Resmetirom |
| Capsovision, INC. | $31.27 | 2025 | Capsocam Plus |
| Takeda Pharmaceuticals U.S.A., INC. | $27.66 | 2025 | Entyvio |
| Progenics Pharmaceuticals, INC. | $25.52 | 2025 | |
| Tg Therapeutics, INC. | $24.57 | 2024 | |
| Alfasigma USA, INC. | $19.14 | 2022 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $18.19 | 2025 | Wegovy |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $17.64 | 2023 | Xifaxan |
| Redhill Biopharma INC. | $14.22 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Yvette David listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.